Rick Simpson Oil (RSO) in Mongmong-Toto-Maite Municipality: The Complete Guide by OilWell Cannabis

For residents of Mongmong-Toto-Maite Municipality facing cancer, chronic pain, PTSD, or the daily struggle of conditions that conventional medicine hasn’t solved, the search for real relief can feel lonely. You’re not alone. Across Guam and throughout the Pacific Islands, people are discovering that cannabinoid medicine—when it’s made with precision, honesty, and respect for the science—can offer options that pharmaceuticals haven’t delivered. This is the story of Rick Simpson Oil, reimagined for our community here in Mongmong-Toto-Maite Municipality, where family matters, resilience runs deep, and access to specialized care can mean traveling to Tamuning or even off-island.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For families in Mongmong-Toto-Maite Municipality who’ve watched loved ones cycle through ineffective prescriptions after being referred from Guam Memorial Hospital to specialists in Hawaii or the mainland, only to be told there are no more options, Simpson’s story resonates across the Pacific.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement that eventually reached even our remote shores in Mongmong-Toto-Maite Municipality.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and 2009. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. The following is the protocol as Simpson described it :

Goal: Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule:

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day. Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2 through 5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period, reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, until the full 60 grams have been consumed.

Administration methods:

• Primary method—oral: Place the dose directly under the tongue (sublingual) or swallow it. Simpson considered oral ingestion the most important route for systemic absorption.
• Secondary method—topical: For skin cancers and external lesions, apply the oil directly to the affected area, cover with a bandage, and change every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method, though he acknowledged inhalation for immediate symptom relief (pain, nausea).

Tolerance and the psychoactive effects:

• Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks.
• He recommended initial doses at night or before bed to sleep through the most intense psychoactive effects.
• He advised patients to avoid driving or operating machinery during the titration period.

Post-protocol maintenance: After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Important context for evaluating this protocol:

• No controlled trial validation. There are no published randomized controlled trials evaluating this specific 60-gram/90-day protocol for any condition.
• Assumes crude, unstandardized material. Actual THC content per gram of traditional RSO varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil per day. Assuming 60 to 90 percent THC content, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications but by his method and materials .

Source material: Simpson used high-THC, indica-dominant cannabis strains. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction solvent: Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid. He later endorsed 99 percent isopropyl alcohol as an alternative. Neither is a food-grade solvent, which creates significant safety risks.

Extraction process: The cannabis material was soaked in solvent, agitated, filtered, and the solvent was evaporated in a rice cooker at relatively low heat. This temperature was still high enough to decarboxylate THCa into THC and destroy most volatile terpenes.

Appearance and physical characteristics: Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with a strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile: Primarily decarboxylated delta-9 THC. Estimated THC content ranged from 60 to 90 percent by weight, though this was never lab-verified. Minor cannabinoids were present at natural ratios but not controlled, measured, or targeted.

Terpene content: Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content.

Standardization and testing: None. Every batch was different because it depended entirely on starting plant material, growing conditions, solvent purity, extraction technique, and the individual maker’s process.

Residual solvent risk: Naphtha may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is difficult to verify without lab testing—leaves potentially harmful residues in the finished oil.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil, stating that RSO could cure cancer and many other diseases. He was adamant, consistent, and public about these claims throughout his advocacy career .

What Simpson was not: He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never conducted or published a clinical trial. His entire evidence base consisted of personal experience and testimonials gathered informally.

What the preclinical literature shows: In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines . Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .

What the preclinical literature does not show: These findings have not translated into proven human cancer cures. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. The gap between in vitro or animal results and human clinical outcomes is vast.

Institutional positions:

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The FDA has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH identifies strongest evidence for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

What Simpson got right: Simpson drew attention to cannabinoids as a serious area of biomedical research when the world was ignoring it. He helped create the political, cultural, and social conditions for the legal cannabis industry. The term “RSO” itself remains the most recognized name for full-spectrum cannabis extract.

What he overstated: Simpson’s cure claims exceeded the evidence. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas available to residents of Mongmong-Toto-Maite Municipality today.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbes
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted
Legal status	Illegal Schedule I	Farm Bill compliant, ships to Mongmong-Toto-Maite Municipality

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other compounds with established toxicity. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the scientific evidence section, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent—was sufficient to convert essentially all THCa in the extract into delta-9 THC. As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited [20][29].

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

The scientific evidence section of this document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences for residents of Mongmong-Toto-Maite Municipality:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower while still delivering therapeutic cannabinoid content.

Dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ)—Health Professional Version. NIH/NCI. Updated 2024.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas, but its mission extends across America and the Pacific, reaching communities like Mongmong-Toto-Maite Municipality where healthcare options can feel limited. Colin grew up in McAllen, Texas—right across the river from Reynosa, Mexico—in one of the most economically challenged and dangerous regions along the U.S.-Mexico border. That childhood taught him about resilience, about watching friends fall to violence or prison, and about looking for safer paths when the world offers only dangerous ones. He chose cannabis over harder paths, learning the plant intimately in the traditional underground before transitioning to legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach and allows us to serve remote communities like Mongmong-Toto-Maite Municipality with the same precision we’d apply in Houston.

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin learned about CBD through a question that changed everything. A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?” Colin had cannabis experience—but it was recreational. He had never explored therapeutic applications.

Determined to save Bentley, Colin created CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

What this means for families in Mongmong-Toto-Maite Municipality: Bentley’s journey mirrors the experience of many elders in our community who face multiple age-related conditions simultaneously. When Guam Memorial Hospital refers patients to off-island specialists for neurodegeneration or when families in Toto-Maite watch loved ones struggle with arthritis that makes walking our hills painful, they’re experiencing what Colin learned: single cannabinoids are not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. The RSO formula that OilWell offers today—seven cannabinoids working together—was born from keeping one dog alive for a decade, not from a marketing department.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including the families of Mongmong-Toto-Maite Municipality who may have specific dietary needs—vegans, diabetics, those managing blood sugar challenges common in our community.

ABC13 Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. When ABC13 needed to explain a new cannabis product, it called Colin. When Texas reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When they wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. But more importantly for you in Mongmong-Toto-Maite Municipality: we ship nationwide and internationally, with full documentation for customs, so that our products can reach Guam and the Pacific Islands legally and reliably.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision—problems that are especially relevant for remote communities like Mongmong-Toto-Maite Municipality.

Four core principles define OilWell’s approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers in Mongmong-Toto-Maite Municipality who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally, even to Pacific Islands where local dispensary access may be limited or non-existent.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. For the working families of Mongmong-Toto-Maite Municipality—where many commute to Tamuning or work at the Naval Base—this means you can use the raw form during the day for inflammation without impairment, then activate it at night for sleep support.

3. Open-source formulas. OilWell publishes our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone in Mongmong-Toto-Maite Municipality who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The scientific evidence section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design and is what makes it possible to ship to Mongmong-Toto-Maite Municipality.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and can be shipped to Guam.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial for Mongmong-Toto-Maite Municipality residents. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

Important legal notice for Mongmong-Toto-Maite Municipality: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws regarding cannabinoid products. Guam legalized medical cannabis in 2014 and recreational cannabis in 2019, though implementation has been gradual. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers (including Guam) accept all customs and legal responsibility. As a U.S. territory, Guam recognizes federal hemp laws, making Farm Bill-compliant products legal to import and possess.

Open-source formulas—why OilWell publishes everything

OilWell publishes our complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone in Mongmong-Toto-Maite Municipality cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas are provided as a resource for our community.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner in Mongmong-Toto-Maite Municipality facing a similar crisis could make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7-10 minutes). Add more water if needed.
2. Add coconut oil and freshly ground black pepper. Stir until thoroughly mixed.
3. Allow to cool, then transfer to a jar with lid. Store in refrigerator for up to two weeks.
4. Add CBD oil to the paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.

Serving suggestion: Mix a small amount with pet’s food once or twice daily. Monitor for changes and consult a veterinarian if concerns arise.

This recipe—published for free, years before the RSO formulas—demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula designed for people.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for customers in Mongmong-Toto-Maite Municipality:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. This option is compatible with work, driving, and daytime use with zero impairment. For the many residents of Mongmong-Toto-Maite Municipality who commute to work at the Naval Base or in Tumuning, this means you can manage inflammation and anxiety during the day without any cognitive impact.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. This is the fastest-onset RSO delivery method available—ideal for breakthrough pain or acute anxiety that needs immediate relief.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production. For residents of Mongmong-Toto-Maite Municipality, where access to analytical testing facilities is limited and product safety concerns are paramount, this solvent-free approach provides assurance that what you’re consuming has been verified clean.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website. For our customers in Mongmong-Toto-Maite Municipality, we include full COA documentation with every shipment to ensure customs clearance and transparency.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans in Guam and across military communities for its ability to relieve pain and PTSD symptoms without being overly aggressive—a consideration for the many service members and veterans who call Mongmong-Toto-Maite Municipality home.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis. For the many residents of Mongmong-Toto-Maite Municipality dealing with trauma, anxiety, or the stress of living in a region prone to typhoons and economic uncertainty, this formula was literally born from shared experience.

Custom creations—OilWell offers custom-made products tailored to the specific needs of individual customers in Mongmong-Toto-Maite Municipality. Whether it involves specific cannabinoid ratios for diabetes management (a condition that affects nearly 15% of adults in Guam), particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs common in our Pacific Island community.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent
• Approximately 40 to 60 doses per bottle

For a typical adult in Mongmong-Toto-Maite Municipality, this means one bottle can provide one to two months of therapeutic support, depending on individual needs and dosing.

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility (batteries available locally in Guam or online)
• Onset: 1 to 2 minutes (fastest delivery)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—critical when you need immediate relief and can’t wait
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for managing conditions through the night
Maximum bioavailability	Sublingual	13-19% absorption, more efficient use of cannabinoids
Portability and discretion	Vape	Compact, no measuring required—easy to carry in Mongmong-Toto-Maite’s tropical climate
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments—essential for titration
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment—perfect for working hours
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full therapeutic and rest effects

Competitive comparison—OilWell RSO vs. alternatives

OilWell RSO vs. Guam dispensary products (if available)

Due to Guam’s slow implementation of its recreational cannabis law (passed in 2019), licensed dispensaries remain limited and primarily serve medical cardholders. For residents of Mongmong-Toto-Maite Municipality, access often requires travel to Tamuning or Agana Heights. OilWell offers:

• No medical card required—available to any adult 21+ in Mongmong-Toto-Maite Municipality
• Ships directly to your home—no travel required, crucial for elders or those with mobility issues
• Seven cannabinoids vs. typically one or two—Guam dispensaries often focus on THC-only products
• Published formula—you know exactly what you’re getting, unlike variable dispensary batches

OilWell RSO vs. online hemp CBD products

Many online retailers ship CBD isolate products to Guam. OilWell’s advantages:

• 16,590 mg total cannabinoids vs. typical 1,000 mg from competitors
• Seven cannabinoids including psychoactive options via THCa conversion
• Live terpenes for entourage effect
• Open-source formula transparency

OilWell RSO vs. traditional illegal RSO

Dimension	Traditional RSO	OilWell RSO
Legal status	Schedule I illegal	Farm Bill compliant, ships to Mongmong-Toto-Maite Municipality
Safety testing	None	Full panel testing, COAs provided
Solvents	Naphtha/isopropanol (toxic)	Solvent-free, MCT oil base
Cannabinoid control	Uncontrolled, variable	Precise mg amounts, seven compounds
Dosing precision	Approximate	Graduated dropper, 553 mg/mL
THCa preservation	No—fully decarbed	Yes—patient controls activation

Condition-specific usage context for Mongmong-Toto-Maite Municipality

Important disclaimer: The following usage contexts are informed by cannabinoid research and OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

For cancer support (during treatment or recovery)

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Note: Many cancer patients from Mongmong-Toto-Maite Municipality travel to Hawaii or the mainland for treatment. Our products can be shipped to your treatment location or back home to Guam.

For chronic pain (diabetes-related neuropathy, arthritis, fibromyalgia)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory effects without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Guam has some of the highest diabetes rates in the U.S. The multi-cannabinoid anti-inflammatory approach (CBD, CBG, THCa, caryophyllene) targets multiple pain pathways simultaneously.

For sleep support (insomnia, disrupted sleep from pain or PTSD)

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance

For veterans and military families in Mongmong-Toto-Maite Municipality dealing with trauma-related sleep issues, this formula was developed by someone who lives with PTSD.

For anxiety and stress (including typhoon-related trauma, work stress, family pressures)

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery to Mongmong-Toto-Maite Municipality

We understand that getting specialized products to Guam requires planning. OilWell ships to Mongmong-Toto-Maite Municipality using:

International shipping to Guam:

• All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• USPS International Priority Mail (7-10 business days) or FedEx International Economy (5-7 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Guam’s tropical climate
• Customer is responsible for verifying legality in Guam and accepts all customs and legal risk

Guam-specific legal context: As a U.S. territory, Guam recognizes federal hemp laws. Medical cannabis was legalized in 2014 and recreational in 2019. However, licensed dispensaries remain limited. Farm Bill-compliant hemp products like OilWell’s RSO are legal to import and possess. We provide all documentation to ensure smooth customs clearance through Antonio B. Won Pat International Airport.

For questions about shipping to Mongmong-Toto-Maite Municipality: Contact us at (832) 416-2816 or [email protected]. We have experience shipping to Guam and can provide specific guidance.

How the OilWell formulas connect to the evidence

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where we make specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

OilWell does not exempt itself from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position—as stated by Colin Valencia in 2019—is that people in Mongmong-Toto-Maite Municipality deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s cannabis authority reaching Mongmong-Toto-Maite Municipality

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

For residents of Mongmong-Toto-Maite Municipality watching via streaming or seeing clips shared online, this media record establishes something important: OilWell is not an anonymous internet brand. We are a real company with verifiable media coverage from a major-market ABC affiliate that repeatedly identified Colin as the most credible voice in Houston’s legal cannabis industry.

September 15, 2019—”Texas CBD businesses booming”
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

May 24, 2021—”What is Delta 8 THC”
When asked why someone would want Delta-8, Colin’s iconic response: “Maybe you want to get high.” This radical honesty on mainstream television—with the expletive preserved—demonstrates our commitment to transparency over hype.

August 20, 2021—”Houston CBD shop giving away free products for COVID vaccine”
OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage vaccination. Colin coordinated with the city of Houston to help public health efforts—real community action, not marketing.

October 19, 2021—”Texas ban over Delta 8″
When Texas reclassified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement and tried to warn other operators who were unknowingly shipping what had become illegal narcotics. Ethical leadership during crisis.

October 7, 2022—”Biden marijuana pardon”
Revealed that Colin has personal marijuana conviction history: “I would love to see people not get hurt for this anymore.” This transforms every other quote—Colin speaks from lived experience, not theory.

April 21, 2023—”Marijuana industry getting creative”
Colin described the current era as a “Renaissance”—a time of opportunity that should be enjoyed now. For Mongmong-Toto-Maite Municipality residents watching Guam’s cannabis program slowly evolve, this framing empowers action rather than waiting.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds in OilWell’s RSO, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• The FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].

Cannabinoid profiles

CBD—Strongest human evidence in seizure disorders [1][2]. A 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical sample [3]. A 2024 pain review concluded promising but heterogeneous results [4]. A 2023 insomnia review found methodologically weak literature [5]. A 2023 safety review found real signal for liver enzyme elevation and possible drug-induced liver injury [6].

CBG—Mostly review-level and preclinical; human evidence remains sparse [7][8]. A 2024 review highlighted therapeutic potential but noted limited clinical validation [8].

Delta-8 THC—Pharmacologically relevant and psychoactive, much less clinically characterized than delta-9 THC [9]-[11]. A 2022 review found similar pharmacokinetic behavior to delta-9 but less potency [9]. A 2023 scoping review emphasized regulatory and product-quality concerns [10].

THCa—Important chemically but low on direct human therapeutic evidence [12]. Does not produce psychoactive effects unless heated. In vitro and rodent literature suggest anti-inflammatory and neuroprotective possibilities, but these are not equivalent to established human outcomes [12].

Delta-9 THC—Strongest human evidence of psychoactive cannabinoids but also clearest adverse-effect burden [1][13]-[15]. FDA-approved for chemotherapy-related nausea and HIV/AIDS appetite loss [1]. A 2022 pain review found short-term benefit but increased dizziness, sedation, and discontinuation [13]. A 2025 review found consistent unfavorable associations with psychosis and cannabis use disorder at high concentrations [15].

CBN—Weak human evidence; marketing has moved ahead of data [12][16][17]. A 2021 sleep review found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16]. A 2024 sleep review concluded overall cannabinoid sleep research still doesn’t match real-world use scale [17].

CBC—Emerging, intriguing, overwhelmingly preclinical [18][19]. A 2024 review argued it has distinct pharmacodynamics and highlighted antinociceptive, antibacterial, and anti-seizure areas as interesting research targets, but noted over-the-counter products are being sold despite little evidence establishing clinical efficacy or safety [18].

Terpene profiles

Limonene—Multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but most claims from nonhuman literature [20]-[22]. Limonene oxidation products are clinically relevant contact allergens [22].

Myrcene—Preclinical evidence for anxiolytic, antioxidant, anti-inflammatory, analgesic properties, but human studies lacking [20][23]. Claims that myrcene reliably explains sedation remain ahead of evidence [23].

Caryophyllene—Selective CB2 receptor agonist, making it especially relevant pharmacologically [24]. Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions discussed, but human clinical confirmation limited [24].

Pinene—Promising preclinical literature for brain health, but weak human clinical confirmation [20][25]. Claims that pinene reliably improves memory or counters THC cognitive effects remain hypotheses [25].

Linalool—Substantial preclinical interest for stress, mood, and brain health, but limited direct clinical confirmation [20][22][25][26]. Oxidized linalool hydroperoxides are recognized allergens [22].

Humulene—Translationally interesting but early [20][27]. A 2024 scoping review found broad preclinical evidence with some rodent work suggesting cannabimimetic properties, but not yet strong evidence for consistent human efficacy [27].

Terpinolene—Least clinically characterized [20][28]. A 2021 systematic review concluded evidence base dominated by in silico, in vitro, and animal studies rather than human trials [28].

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation [1][10][11][14].
• For THCa, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids [12].

Common overstatements to avoid

• CBN as proven sleep aid—Specific sleep evidence remains weak [16][17].
• Myrcene as proven sedative—Direct human proof limited [23].
• Terpenes have proven entourage effects—Robust clinical proof remains limited [20][29].
• THCa is always nonpsychoactive—Heating and processing can convert THCa to THC [12].
• Delta-8 THC is safe because hemp-derived—Psychoactive, pharmacologically close to delta-9, with manufacturing/testing concerns [9]-[11].

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Price: $129.99
• Carrier: Organic MCT oil
• Dosing: Graduated dropper in 0.1 mL increments

This is the complete open-source formula. If you cannot afford the product, source these ingredients and make your own. The knowledge belongs to the community.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Thread: 510 universal (compatible with standard batteries available in Mongmong-Toto-Maite Municipality)
• Activation: Auto-decarboxylation at 400-450°F
• Price: $49.99

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene—Citrus-bright, mood-elevating, stress-reducing
• Myrcene—Earthy, relaxing, potentially sedating
• Caryophyllene—Pepper/spice, CB2 agonist, anti-inflammatory
• Pinene—Forest-fresh, alertness, memory support
• Linalool—Floral lavender, calming, anxiety-reducing
• Humulene—Earthy woody, anti-inflammatory, appetite-suppressing
• Terpinolene—Piney fruity, antioxidant, uplifting

For the people of Mongmong-Toto-Maite Municipality, these terpenes connect to familiar island aromas—the citrus groves, pine stands, and floral gardens that surround our homes. The terpene profile makes the product experience as sensory as it is therapeutic.

FINAL THOUGHTS FOR MONGMONG-TOTO-MAITE MUNICIPALITY

Every family in Mongmong-Toto-Maite Municipality knows someone who has faced the limits of conventional medicine. Whether it’s a veteran at the Naval Base dealing with PTSD, a grandparent struggling with diabetes-related neuropathy, or a cancer patient traveling to Honolulu for treatment only to be told “there’s nothing more we can do”—the need for options is real.

OilWell Cannabis was built from the same desperation that drives people in Mongmong-Toto-Maite Municipality to search for alternatives. Colin’s story—from McAllen border danger to Bentley’s recovery to his own benzo withdrawal—is not corporate marketing. It’s lived experience turned into formulated medicine.

We don’t claim RSO cures cancer. We don’t promise miracles. We provide a product that is:

• Legal—Farm Bill compliant, ships to Guam with full documentation
• Transparent—every ingredient published, nothing hidden
• Flexible—you control the psychoactivity level
• Evidence-informed—backed by peer-reviewed research, not hype
• Accessible—no medical card required, ships directly to Mongmong-Toto-Maite Municipality

The people of Mongmong-Toto-Maite Municipality deserve the same quality and transparency as customers in Houston, Los Angeles, or New York. We don’t water down our formulas for remote markets. The same 16,590 mg total cannabinoids, the same seven-terpene profile, the same third-party lab testing—we ship our best to Guam because your health matters just as much.

Ready to order for delivery to Mongmong-Toto-Maite Municipality?

Visit OilWellCBD.com or call (832) 416-2816. We ship to Guam weekly and can answer any questions about customs, dosing, or product selection for your specific needs.